Introduction {#s1}
============

The mitogen activated protein kinase (MAPK) pathway is one of the most crucial pathways in regulation of cancer cell proliferation and survival [@pone.0047054-Kyriakis1]. Constitutive activation of the MAPK pathway in cancers has been frequently observed in various malignancies which is usually due to activating mutations in upstream factors such as RAS and RAF [@pone.0047054-Malumbres1]. Accordingly, mutations in *BRAF* are reported in up to 70% of cancer cell lines [@pone.0047054-Davies1] and they are highly prevalent in most common cancers with poor prognosis such as malignant melanoma [@pone.0047054-Davies1], [@pone.0047054-Brose1]. Mutations in *BRAF* have been reported in up to 60% of melanoma cases, between 40 to 70% of thyroid carcinomas, and up to 18% of colorectal cancers [@pone.0047054-Davies1], [@pone.0047054-Cohen1].

So far, over 50 distinct mutations have been identified in the *BRAF* gene, which are present either in the glycine-rich P-loop of the N lobe or the activating segment in the exon 15 region [@pone.0047054-Wan1]. Most of these mutations increase BRAF activity by 1.5 to 700 folds depending on the type of the mutation [@pone.0047054-Wan1]. Of all *BRAF* activating mutations, a transitional mutation in nucleotide 1799 (T-A), also known as *BRAF*-V600E, is the most common change. In fact, this single mutation dramatically increases BRAF activity and accounts for more than 80% of all reported *BRAF* mutations in tumors [@pone.0047054-Davies1], [@pone.0047054-Wan1]. This point mutation results in a valine to glutamic acid substitution that exposes the active site (normally sealed in a hydrophobic pouch) and implicates the constitutive activation of BRAF. As a result, malignant cells with V600E mutation proliferate in a growth factor-independent manner in culture as well as in tumors in animal models [@pone.0047054-Wellbrock1]. In addition, it has been demonstrated that *BRAF* mutation is highly involved in main steps of cancer development and progression [@pone.0047054-Hoeflich1]. Together, these reports nominate the *BRAF*-V600E mutation as a very promising therapeutic target in *BRAF* mutated cancers. So far, BRAF inhibitor PLX4032 is one of the only few promising treatments for malignant melanoma approved by the US Food and Drug Administration.

Although there are multiple reports on the correlation of *BRAF* mutation with a variety of cancer progression steps, the correlation between *BRAF* mutation and cancer patient survival is still a matter of controversy in different reports [@pone.0047054-VanCutsem1]--[@pone.0047054-Chang1]. In this study, we used systematic review and meta-analysis as the most reliable approach to investigate whether *BRAF-*V600E mutation is associated with patient outcome. A pool of studies published between 2002 and 2011 on the association between *BRAF*-V600E mutation and patient survival in colorectal cancer, malignant melanoma and papillary thyroid carcinoma were reviewed and analyzed for this study. We found that *BRAF* mutation increases the risk of mortality in colorectal cancer patients by more than two-fold. In addition, we revealed that *BRAF*-*V600E* mutation also increases the risk of mortality in melanoma patients by 1.7 times, while its effect on papillary thyroid carcinoma still requires further investigation.

Methods {#s2}
=======

Search Strategy and Selection Criteria {#s2a}
--------------------------------------

We conducted a comprehensive search of medical literature on studies evaluating the effect of *BRAF*-V600E mutation on cancer patient survival. We searched MEDLINE and EMBASE using the terms "*BRAF*", "*BRAF* mutation", "*BRAF* V600E", "cancer", "patient survival", "colorectal cancer", "melanoma", and "papillary thyroid carcinoma" in different combinations from June 2002 to December 2011. We initially narrowed our search based on research title followed by abstract and finally full texts were reviewed if they were categorized as relevant reports. We did not restrict the language in our research. All of the references from review papers and original reports were checked for further relevant studies in the systematic review.

Studies were excluded if contained no clinicopathologic data, survival analysis, or no comparison between wild type and mutant *BRAF*. In addition, studies which only reported a progression free survival as well as *in vitro* and animal reports were also excluded. For more information in detail please refer to PRISMA checklist ([Table S1](#pone.0047054.s002){ref-type="supplementary-material"}).

Data Extraction and Study Assessment {#s2b}
------------------------------------

Two independent reviewers (GSA and LT) reviewed each full text report for eligibility and extracted required data. For each study the data on the number of patients in each group, mean survival time, hazard ratio and mean progression free survival time for randomized controlled trials (RCT), cancer type and study design were obtained and a consensus was achieved on all items. In the cases of incomplete required information, authors were contacted for additional information which was added as best as possible. Duplication of data was avoided by matching the author's name and the name of the research centers.

Statistical Analysis {#s2c}
--------------------

We started summarizing the effect of *BRAF*-V600E mutation on patient survival separately based on study design RCT versus cohort and cancer type. We evaluated the publication bias using funnel plot analysis. We also assessed the heterogeneity of the studies using chi-square test of heterogeneity and I^2^ measure of inconsistency. Significant heterogeneity was defined as a Chi-square test *P* value of \<0.10 or as an I^2^ measure \>50%. Estimated hazard ratio (HR) was calculated using odds ratio and confidence interval in studies where HR was not available. In the absence of heterogeneity HRs and CIs were calculated according to a fixed model [@pone.0047054-Greenland1] which assumes that results across studies differ only by sampling error. In those studies where only the survival curve was available with no other detailed information, survival rates were extracted over multiple time periods in order to reconstruct HR and its variance with the assumption that patient censor rate was constant during study follow-up. This method has been described previously by Parmar *et al.* [@pone.0047054-Parmar1] to extract summary statistics for meta-analysis. A HR\>1 was considered as a risk factor for worse survival in patient with positive *BRAF* mutation. In the end we used a log hazard ratio in the pooled data for the final analysis using R software (2011, The R Foundation for Statistical Computing). The impact of *BRAF* mutation on patient survival was considered statistically significant if 95% confidence interval for individual or overall log HR did not overlap zero.

Results {#s3}
=======

Number of Studies {#s3a}
-----------------

A total of 565 studies were retrieved from our electronic search. Of these, 120 abstracts were considered relevant and full texts were reviewed in detail. By the end of the review 26 studies on colorectal cancer (5 RCTs and 21 cohorts; 11,773 patients) met our inclusion criteria for meta-analysis. In addition, four studies on melanoma (1 RCT and 3 cohorts; 674 patients) including one study published at the time of statistical analysis [@pone.0047054-Si1] were incorporated in our final meta-analysis ([Figure 1](#pone-0047054-g001){ref-type="fig"}). Please also refer to complete PRISMA flow diagram ([Figure S1](#pone.0047054.s001){ref-type="supplementary-material"}) for more information. We were able to extract the overall survival information from two studies on papillary thyroid carcinoma [@pone.0047054-Musholt1], [@pone.0047054-Elisei1]. However, we did not perform meta-analysis on papillary thyroid carcinoma subject due to the small number of studies ([Table 1](#pone-0047054-t001){ref-type="table"}). The funnel plot for colorectal cancer but not for melanoma studies showed a publication bias in our collected data.

![Flow diagram demonstrates the study selection process.](pone.0047054.g001){#pone-0047054-g001}

10.1371/journal.pone.0047054.t001

###### Summary of studies that evaluated the impact of *BRAF* mutation on overall patient survival in colorectal cancer and melanoma.

![](pone.0047054.t001){#pone-0047054-t001-1}

                                                                  Country      Studydesign   Number of patients   Overall survival   Hazard ratio                             
  ----------------------------------------------------------- --------------- ------------- -------------------- ------------------ -------------- ------------ ------ ------ --------------------
  **COLORECTAL CANCER**                                                                                                                                                       
  **Barault L** [@pone.0047054-Barault1]                          France         Cohort             582                 582              506        76(13.1%)                   1.2(0.55--2.61)
  **De Roock W** [@pone.0047054-DeRoock1]                         Belgium        Cohort             886                 761              725         36(4.7%)     26     54     2.93(1.85--4.65)
  **Farina-Sarasqueta A** [@pone.0047054-FarinaSarasqueta1]     Netherland       Cohort             258                 203              165         38(18.7)                   2.22(0.87--3.57)
  **Ferracin M** [@pone.0047054-Ferracin1]                         Italy         Cohort              93                  79               72         7(8.9%)                          3.37
  **French AJ** [@pone.0047054-French1]                             USA          Cohort             533                 490              413        77(15.7%)     71     68      1.2(0.8--1.8)
  **Laurent-Puig P** [@pone.0047054-LaurentPuig1]                 France         Cohort             173                 115              110         5(4.3%)     14.4   17.9  
  **Liao W** [@pone.0047054-Liao1]                                 China         Cohort              61                  61               58         3(4.9%)      9      11    2.016(0.61--6.58)
  **Liou JM** [@pone.0047054-Liou1]                               Taiwan         Cohort             314                 314              302         12(3.8%)                  3.91(1.31--11.66)
  **Loupakis F** [@pone.0047054-Loupakis1]                         Italy         Cohort             138                  87               74        13(14.9%)    4.1    13.1    1.96(0.48--3.44)
  **Maestro ML** [@pone.0047054-Maestro1]                          Spain         Cohort             351                 324              312         12(3.7%)     41     68     1.62(0.50--5.21)
  **Maughan TS** [@pone.0047054-Maughan1]                           UK             RCT              1630                1291             1189       102(7.9%)    8.8    14.4  
  **Ogino S** [@pone.0047054-Ogino1]                                USA          Cohort             649                 631              526        105(16.6%)                  1.97(1.13--3.42)
  **Park JH** [@pone.0047054-Park1]                                Korea         Cohort              75                  71               66          5(7%)      2.46   7.53          3.06
  **Price TJ** [@pone.0047054-Price1]                            Australia       Cohort             471                 315              282        33(10.5%)    8.6    20.8    2.04(1.20--2.87)
  **Richman SD** [@pone.0047054-Richman1]                           UK             RCT              2135                692              638         54(7.8%)                   1.82(1.36--2.43)
  **Roth AD** [@pone.0047054-Roth1]                             Switzerland        RCT              1404                1307             1204       103(7.9%)                   1.59(0.65--3.91)
  **Samowitz WS** [@pone.0047054-Samowitz1]                         USA          Cohort             763                 763              723         40(5.2%)                  4.23(1.65--10.84)
  **Saridaki Z** [@pone.0047054-Saridaki1]                        Greece         Cohort             112                 112              104         8(7.1%)     4.3    15.1     3.6(1.7--7.5)
  **Shaukat A** [@pone.0047054-Shaukat1]                            USA          Cohort             194                 165              129        36(21.8%)                   1.95(1.18--3.20)
  **Souglakos J** [@pone.0047054-Souglakos1]                    Greece/USA       Cohort             168                 168              155         13(7.7%)    10.9   40.5     4.5(2.4--8.4)
  **Tie J** [@pone.0047054-Tie1]                                 Australia       Cohort             525                 525              473         52(9.9%)    2.8    13.5    2.48(1.31--4.72)
  **Tol J** [@pone.0047054-Tol1]                                Netherland         RCT              559                 518              473         45(8.7%)    12.9   24.5          3.2
  **Tran B** [@pone.0047054-Tran1]                             Australia/USA     Cohort             524                 524              467        57(10.9%)    10.4   34.7   11.11(6.27--19.17)
  **Van Cutsem E** [@pone.0047054-VanCutsem1]                     Belgium          RCT              999                 625              566         59(9.4%)    14.1   25.1    1.1(0.42--1.78)
  **Yokota T** [@pone.0047054-Yokota1]                             Japan         Cohort             319                 229              214         15(6.5%)     11    40.6    4.23(1.76--10.2)
  **Zlobec I** [@pone.0047054-Zlobec1] **(Left side)**          Switzerland      Cohort             404                 242              223         19(7.9%)                    0.53(0.3--1.2)
  **Zlobec I** [@pone.0047054-Zlobec1] **(Right side)**         Switzerland      Cohort             404                 127              102        25 (19.7%)                   2.82(1.5--5.5)
  **MELANOMA**                                                                                                                                                                
  **Kumar R** [@pone.0047054-Kumar2]                              Finland        Cohort              38                  38               12        26 (68.4%)                  2.16(1.02--4.59)
  **Long GV** [@pone.0047054-Long1]                              Australia       Cohort             197                 197              102        95 (48.2%)   11.1   46.1  
  **Si L** [@pone.0047054-Si1]                                     China         Cohort             432                 395              297        98 (24.8%)    33     53     1.54(1.11--2.12)
  **von Moos R** [@pone.0047054-vonMoos1]                       Switzerland        RCT               62                  44               22        22 (50.0%)   9.2     12   

Impact of *BRAF-V600e* Mutation on Colorectal Cancer Patient Survival {#s3b}
---------------------------------------------------------------------

In our pooled data for colorectal cancer only one paper reported a protective HR (less than one) for *BRAF* mutation. Accordingly, Zlobec *et al* [@pone.0047054-Zlobec1] observed a protective HR of 0.53 (0.3--1.3) for left side colon cancer. However, they reported a higher HR of 2.82 (1.5--5.5) for *BRAF* mutation as a risk factor for right side colon cancer in the same report. We considered these two analyses as separate reports in our final analysis. The pooled log HR of *BRAF* mutation effect on patient survival in colorectal cancer for cohort and RCT studies were 0.88 (0.60--1.16) and 0.61 (0.28--0.94), respectively. The final log HR for all studies on colorectal cancer was 0.81 (0.60--1.03) which corresponds to a HR of 2.24 (1.82--2.83, 95% CI). The heterogeneity of data on colorectal cancer was significant (*P*\<0.0001) and I^2^ estimate of variation between analyzed studies was 74.3% ([Figure 2](#pone-0047054-g002){ref-type="fig"}).

![Random effect model of Log hazard ratio (LogHR) with 95% confidence interval for studies comparing the effect of *BRAF-*V600E mutation on overall survival of colorectal cancer patients.\
A LogHR \<0 implies a survival benefit for patients with *BRAF* mutation. The square size indicates the power of each study in meta-analysis based on the number of patients in that study. The center of diamond shape at the lowest part indicates the combined LogHR for meta-analysis and its extremities the 95% confidence interval.](pone.0047054.g002){#pone-0047054-g002}

Impact of *BRAF-V600e* Mutation on Melanoma Patient Survival {#s3c}
------------------------------------------------------------

One RCT study [@pone.0047054-Board1] compared *BRAF* mutation in patients' serum level with tumor samples but had no data on wild type *BRAF* status. Two other RCTs evaluated progression-free survival (PFS) with either no overall survival information [@pone.0047054-Amaravadi1] and non-significant PFS or no overall survival data on wild type *BRAF* group [@pone.0047054-Flaherty1]. One cohort study used age \<55 years as a surrogate marker for *BRAF* mutation while others either reported PFS or non-significant difference with no detailed information or survival curve graphs ([Table 1](#pone-0047054-t001){ref-type="table"}). Pooled log HR for *BRAF* mutation effect on patient survival in melanoma for cohort studies was 0.57 (0.35--0.80) and the final pooled log HR including one RCT was 0.53 (0.32--0.75) corresponding to a HR of 1.70 (1.37--2.12, 95% CI). The heterogeneity of the data was not significant (*P* = 0.467) and I^2^ estimate of variation between analyzed studies was 0.0% ([Figure 3](#pone-0047054-g003){ref-type="fig"}).

![Random effect model of Log hazard ratio (LogHR) with 95% confidence interval for studies comparing the effect of *BRAF-*V600E mutation on overall survival in melanoma patients.\
A LogHR \<0 implies a survival benefit for patients with *BRAF* mutation. The square size indicates the power of each study in meta-analysis based on the number of patients in that study. The center of diamond shape at the lowest part indicates the combined LogHR for meta-analysis and its extremities the 95% confidence interval.](pone.0047054.g003){#pone-0047054-g003}

Impact of *BRAF-V600e* Mutation on Papillary Thyroid Carcinoma Patient Survival {#s3d}
-------------------------------------------------------------------------------

One study [@pone.0047054-ONeill1] reported no death in wild type *BRAF* group after almost 221 months of follow up. Another study [@pone.0047054-Elisei1] reported just one death in wild-type *BRAF* group after 20 years of follow up with odds ratio of 14.63 (1.28--167.29) for mutant *BRAF*. The study by Musholt *et al* [@pone.0047054-Musholt1] reported no difference in overall survival (HR = 1.04), while two other reports [@pone.0047054-Stanojevic1], [@pone.0047054-Ito1] showed no difference in disease-free survival between mutant and wild-type *BRAF* patients. However, another study by Abubaker *et al* [@pone.0047054-Abubaker1] found *BRAF* mutation as a risk factor for disease free survival and Costa *et al* [@pone.0047054-Costa1] reported that *BRAF* mutation would affect patient survival only if it is considered in combination with other mutations but not alone. In addition, Wang *et al* [@pone.0047054-Wang1] reported that patients with synchronous bilateral papillary thyroid carcinoma, which harbor more *BRAF* mutation, have worse survival compared with those who have unilateral papillary thyroid carcinoma ([Table 2](#pone-0047054-t002){ref-type="table"}).

10.1371/journal.pone.0047054.t002

###### Summary of studies that reported the status of *BRAF* mutation in papillary thyroid carcinoma with information on patient survival.

![](pone.0047054.t002){#pone-0047054-t002-2}

                                                  Number of patients       Overall survival        Hazard ratio     Progression free survival                                         Hazard ratio                                                                                              
  ---------------------------------------------- -------------------- --------------------------- -------------- -------------------------------- ------------------------------------------------------------------------------------ -- ------------------------- --------------------- ----- ------------------
  **Abubaker J** [@pone.0047054-Abubaker1]               536                      296                  143                 153 (51.7%)                                                                                                                                      Poor                
  **Costa AM** [@pone.0047054-Costa1]                     49                      49                    22                   27 (55%)                                No diff.Poor, when combined with other markers                                                                             
  **Elisei R** [@pone.0047054-Elisei1]                   102                      102                   64                  38 (37.3%)                                                 Sig. Lower                                          OR 14.63 (1.28--167.29)                              
  **Ito Y** [@pone.0047054-Ito1]                         631                      631                  389                 242 (38.4%)                                                                                                                                   DFSNo diff.            
  **Musholt TJ** [@pone.0047054-Musholt1]                290                      290                  168                  122 (42%)                                                   No diff.                                                    1.04                                        
  **Oler G** [@pone.0047054-Oler1]                                                120                   62                   57 (48%)                                                                                                                                No data on survival        
  **O'Neill CJ** [@pone.0047054-ONeill1]                 104                      101                   41                   60 (59%)                                                                                                                                        80%           75%  
  **Stanojevic B** [@pone.0047054-Stanojevic1]                                    266                  182                  84 (31.6%)                                                                                                                                  DFS.No diff.             1.15(0.42--3.19)
  **Wang W** [@pone.0047054-Wang1]                    891177714        20867 (SBiPTC)141 (UiPTC)      932370      115(55.3%)44 (65.7%)71 (50.4%)   SBiPTC with more *BRAF* mutation had lower survival compared toUiPTC (*P* = 0.091)                                                           
  **Xing M** [@pone.0047054-Xing1]                                                219                  112                 107 (48.9%)                                        Recurrence free probability                                                                                       

DFS, Disease free survival; OR, Odds Ratio; SBiPTC, Synchronous bilateral papillary thyroid carcinoma; UiPTC, Unilateral papillary thyroid carcinoma.

Discussion {#s4}
==========

*BRAF* mutation has become an important research topic in cancer biology since the original observation by Davies *et al* [@pone.0047054-Davies1] in 2002. They revealed that high frequency of *BRAF* mutation is a common phenomenon in multiple types of cancers. Since then, numerous studies investigated the role of *BRAF* mutation in cancer development and progression. In mechanistic point of view, *BRAF*-V600E mutation, as the most prevalent *BRAF* mutation, changes the inactive conformation of BRAF kinase to a very active state [@pone.0047054-Wan1]. This simple point mutation leads to a constitutive activation of whole MAPK pathway, which mediates the cell surface growth signals to transcriptional activity of cell cycle regulatory genes. The key regulatory role of *BRAF* mutation in MAPK activation especially in melanoma generated a tremendous research effort to block this signaling pathway for cancer treatment. The usage of most available multi-kinase inhibitor at that time, sorafenib, was the first step toward targeted BRAF inhibition. Despite the first promising results in cell culture and animal studies, sorafenib was found to be unsuccessful in melanoma patients treatment even among those harboring mutant *BRAF* [@pone.0047054-Sharma1], [@pone.0047054-Hauschild1]. A number of other small molecule inhibitors have been tested for targeted BRAF inhibition; however, so far only PLX4032 and GSK2118436 have successfully been used in clinical stages [@pone.0047054-Bollag1], [@pone.0047054-Hauschild2]. Taking everything into account, the main goal in cancer treatment is to increase patient survival, while the idea of whether *BRAF* mutation per se actually affects patient survival has been a matter of debate. In this study, by conducting meta-analysis on data reported in 30 independent studies, we evaluated the effect of *BRAF*-V600E mutation on patient survival in colorectal cancer and melanoma. We also reviewed another 10 independent studies on papillary thyroid carcinoma in which *BRAF* mutation is prevalent.

In a population of 11,773 patients from 26 independent studies, we found that the risk of mortality in colorectal cancer patients harboring *BRAF*-V600E mutation is more than two times higher than those with wild-type *BRAF*. We also demonstrated that melanoma patients with *BRAF* mutation have a 1.7 times higher risk of mortality when compared with their counterparts without *BRAF* mutation in a population of 674 patients from the pooled result of 4 studies. In fact, this significant hazard ratio for *BRAF* mutation in our study can indirectly explain the previously reported promising improvement of melanoma patient survival harboring *BRAF* mutation after selective BRAF inhibitor treatments [@pone.0047054-Hauschild2]--[@pone.0047054-Richman1]. However, short period of symptom free survival and resistance to drug therapy are new emerging problems in BRAF specific inhibitor treatments in melanoma patients. Although the preliminary results for BRAF inhibitor treatments were promising, resistance to drug treatment usually appears in almost all cases [@pone.0047054-Flaherty1], [@pone.0047054-Chapman1]. Typically a reactivation of MAPK pathway happens in resistant cases through other mechanisms including RAS or MEK1 mutations, COT overexpression or BRAF truncation [@pone.0047054-Paraiso1]--[@pone.0047054-Wagle1]. Nevertheless, the response rate of colon cancer patients harboring *BRAF*-V600E mutation to BRAF inhibitor treatment is much lower than melanoma patients [@pone.0047054-Kopetz1], [@pone.0047054-Roth1]. In fact, over activation and crosstalk of parallel pathways like phosphatidylinositol 3-kinase (PI3 kinase) -- AKT with MAPK in colorectal cancer is playing a main role in the observed different response to BRAF inhibitor treatments in colorectal cancer. Likewise, a very recent study by Prahallad *et al* [@pone.0047054-Prahallad1] revealed the important role of epidermal growth factor receptor (EGFR) activation in colon cancer patients as well. They showed that a feedback activation of EGFR occurs in colon cancer cells after *BRAF*-V600E inhibition very quickly. In fact, this feedback activation of EGFR in colon cancer cells leads to a continuous malignant cell proliferation even in the presence of *BRAF*-V600E inhibition. However, this mechanism would not be applicable to melanoma cells as they express a very low level of EGFR [@pone.0047054-Prahallad1].

*BRAF* mutation in papillary thyroid cancer was reported to be a risk factor for worse survival in two studies [@pone.0047054-Elisei1], [@pone.0047054-ONeill1]. Notwithstanding a notably long term follow-up of patients for 18 to 20 years in these studies from Australia and Italy, the authors either did not observe any death [@pone.0047054-ONeill1] or only one death [@pone.0047054-Elisei1] in *BRAF* wild-type group of patients. Authors reported only one death in a population of 64 or no death among 41 wild-type *BRAF* patients while Standardized Death Rate for general population in Australia was found to be 6.9 and 4.7 per 1000 standard populations for male and female respectively ([http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by+Subject/4125.0∼Jul+2011∼Main+Features∼Death+rate∼3210](mailto:http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by+Subject/4125.0∼Jul+2011∼Main+Features∼Death+rate∼3210)). Also, based on the report from the Centers for Disease Control and Prevention, age specific mortality rate for normal population within the same age group as patients in these two studies (45 to 54 years) is 420.9 per 100,000 of population (<http://www.cdc.gov/nchs/nvss/mortality_tables.htm>). Altogether, it seems that more studies with larger sample size are required to determine the significance of *BRAF*-V600E mutation effect on papillary thyroid carcinoma patient survival.

The number of studies comparing molecular and clinicopathological difference between right and left side colon cancers have been increased during the past two decades. For instance, a higher frequency of microsatellite instability, which is a poor prognostic factor for colon cancer, has been reported to be more prevalent in right side compared with left side colon cancer [@pone.0047054-Nash1], [@pone.0047054-Rampazzo1]. A number of studies also reported more prevalent *BRAF* mutations in right side colon cancer [@pone.0047054-Zlobec1], [@pone.0047054-FarinaSarasqueta1]. Although different biological and clinicopathological characteristics have been described for right and left side colon cancer, this issue is still a matter of controversy. Accordingly, investigating a large number of patients (29,568) in a recent study, Benedix et al [@pone.0047054-Benedix1] revealed a remarkable clinicopathological variation among colonic subsites irrespective of the side of tumor (right versus left). They showed that these differences are more related to the anatomical site of the cancer origin rather than a simple right and left categorization [@pone.0047054-Benedix1], [@pone.0047054-Benedix2]. Despite a number of descriptive reports on the prevalence of *BRAF* mutation and its correlation with clinicopathological characteristics, there has been no comprehensive comparison on the effect of *BRAF* mutation on patient survival in separate groups of right and left side colon cancers. Accordingly, a controversial favorable effect for *BRAF* mutation on patient survival on left side colon cancer (*P* = 0.084) has been reported by Zlobec *et al* [@pone.0047054-Zlobec1], while in the same study they observed a significant negative effect of *BRAF* mutation on patient survival for right side colon cancer (*P* = 0.01). They did observe a significant protective effect for *BRAF* mutation on left side colon cancer considering other risk factors in a multifactorial analysis (HR, 0.53; *P* = 0.109). However, the negative effect of *BRAF* mutation on right side colon cancer patient survival was persistently significant in multifactorial analysis (HR, 2.82; *P* = 0.002) [@pone.0047054-Zlobec1]. A number of other researchers from our pooled studies also observed a considerable decrease in patient survival with *BRAF* mutation compared with wild-type *BRAF*; however, the specific HR for wild-type or mutant BRAF was not determined [@pone.0047054-VanCutsem1], [@pone.0047054-FarinaSarasqueta1], [@pone.0047054-Loupakis1], [@pone.0047054-Price1]. Based on the significantly poor patient survival in mutant *BRAF* group in those studies according to survival curves and reported survival time difference, we estimated the HR of mutant *BRAF* in our meta-analysis.

With respect to reports on melanoma, Ellerhorst *et al* [@pone.0047054-Ellerhorst1] reported no difference in patient survival between a group of patients with either *BRAF* mutation (109 cases) or *NRAS* mutation (31 cases) and wild-type *BRAF/NRAS* group (80 cases). There was no data available for the effect of *BRAF* mutation alone on patient survival in this report. In a very similar study, Houben *et al* [@pone.0047054-Houben1] evaluated the effect of combined mutation of *BRAF* and *NRAS* mutation in 200 patients and reported a poor overall survival prognosis for metastatic samples which harbor either *BRAF* or *NRAS* mutation. However, they did not observe the same pattern in primary melanoma patients. As these two reports did not provide any information on the effect of *BRAF* mutation per se on patient survival we did not include them in our final meta-analysis. The inconsistency of results in these reports could be due to the fact that they combined *BRAF* and *NRAS* mutation and classified this group of patients together. In addition, Akslen *et al* [@pone.0047054-Akslen1] and Chang *et al* [@pone.0047054-Chang1] reported no difference in patient survival in 69 and 68 cases respectively according to their *BRAF* mutation status. However, no details on patient survival have been provided in these reports. Akslen *et al* [@pone.0047054-Akslen1] mostly focused on different *BRAF* and *NRAS* mutations and their combinations and possible correlation with clinicopathologic characteristics. They reported that *BRAF* and *NRAS* mutations are mutually exclusive except for one case but they did not find any correlation with tumor cell proliferation, thickness or vascular invasion. Although they reported a median follow-up time of 76 months for the patients, no detailed information on mean survival time in each arm of the study was provided. There was no survival curve available in this report either. In a separate study, Chang *et al* [@pone.0047054-Chang1] observed a significant trend for liver metastasis and tendency for multiple organ metastasis in *BRAF* mutant group but they did not detect a significant difference in either clinicopathological characteristics or in patient survival. Basically in this study authors chose a descriptive method to explain their observation and just mentioned that they did not find any correlation between patient survival and *BRAF* mutation. Unfortunately, no more detailed information including mean survival time in each group of study or a survival graph has been provided by the authors. A need for a conclusive meta-analysis on the effect of *BRAF* mutation on melanoma patient survival has been emerged due to the controversial reports on this issue. In our meta-analysis, we combined the results of four independent studies and measured the pooled risk of *BRAF* mutation on melanoma patient survival. So far our report is the first study on this issue which demonstrates the correlation between *BRAF* mutation and poor melanoma patient survival in a reliable statistical point of view. The number of reports on *BRAF* mutation and colorectal cancer were enough to pool the results together and perform a meta-analysis. Therefore, our findings in the pooled data suggest that with successful BRAF inhibition we would be able to increase the survival of colorectal cancer and melanoma patients harboring *BRAF* mutation.

BRAF plays a very important role in cancer initiation and progression. Mutation of *BRAF* is detected in all stages of melanocytic lesions including nevi, primary and metastatic melanoma. It is known to be involved in the multiple stages of tumor progression such as cell proliferation [@pone.0047054-Kumar1] and invasion [@pone.0047054-Hoeflich1]. Interestingly, BRAF has also been shown to be involved in the progression of melanoma toward metastasis by enhancing its migration [@pone.0047054-Arozarena1]. However, cancer is a complex disease with multiple markers being involved in its formation and progression. Therefore, simultaneous study of other factors involved in BRAF network is crucial for a better understanding of its role in cancer. For instance, the cooperation between *BRAF* mutation and PTEN loss in melanoma progression has been identified [@pone.0047054-Dankort1]. Since improving patient survival is the main goal in cancer treatment, further meta-analysis evaluation on the combination of markers involved in this critical network including *RAS* and *PTEN* with *BRAF* seems necessary for future planning in cancer treatment and drug development.

In summary, we used systematic review and meta-analysis approach to investigate possible association between *BRAF*-V600E mutation and cancer patient survival. We found that *BRAF*-V600E mutation increases the risk of mortality in colorectal cancer patients for more than two-fold. In addition, we revealed that *BRAF*-V600E mutation also significantly increases the risk of mortality in melanoma patients. This data highlights the important role of mutant *BRAF* in patient survival and suggest that with successful BRAF inhibition we may be able to increase the survival of colorectal cancer and melanoma patients harboring *BRAF* mutation.
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